INC280: Clinical Trials

16 trials of INC280, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 5 terminated, 1 active not recruiting, 1 recruiting. 16 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 116Completed 9, Terminated 5, Active not recruiting 1, Recruiting 1
Phase 24Terminated 2, Completed 1, Recruiting 1

Follow INC280: new trials by email Literature Review of INC280 trials Research Report on INC280

Trials (filtered) newest first · largest first

All 16 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation
Capmatinib, Trametinib - Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer
Phase 1TerminatedCollin Blakely32022-08-102024-06-11
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
spartalizumab, LAG525, NIR178 - Triple Negative Breast Cancer (TNBC)
Phase 1TerminatedNovartis Pharmaceuticals642019-01-312025-05-18
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC
EGF816, trametinib, ribociclib - EGFR-mutant Non-small Cell Lung Cancer
Phase 1Active not recruitingNovartis Pharmaceuticals1052018-01-292026-11-05
A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.
INC280 - cMET Dysegulation Advanced Solid Tumors
Phase 1CompletedNovartis Pharmaceuticals362016-12-142020-12-19
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Ribociclib, Topotecan, Temozolomide - Pediatric Cancer
Phase 1 / Phase 2RecruitingGustave Roussy, Cancer Campus, Grand Paris4722016-08-032026-07-10
Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC
Spartalizumab, Capmatinib - Advanced Hepatocellular Carcinoma
Phase 1 / Phase 2CompletedNovartis Pharmaceuticals892016-06-152023-07-03
A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
INC280, Midazolam, Caffeine - cMET-dysregulated Advanced Solid Tumors
Phase 1CompletedNovartis Pharmaceuticals372015-12-102020-12-10
A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
INC280, digoxin, rosuvastatin - cMET-dysregulated Advanced Solid Tumors
Phase 1CompletedNovartis Pharmaceuticals322015-12-082020-12-10
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
INC280, bevacizumab - Glioblastoma Multiforme, Gliosarcoma
Phase 1CompletedSCRI Development Innovations, LLC652015-09-222023-09-21
INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function
INC280 - Hepatic Impairment
Phase 1CompletedNovartis Pharmaceuticals312015-06-122020-12-10
Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.
Capmatinib, Nazartinib - Non Small Cell Lung Cancer
Phase 1 / Phase 2TerminatedNovartis Pharmaceuticals1772015-01-132023-06-18
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
INC280, cetuximab - Squamous Cell Carcinoma of Head and Neck (SCCHN), Metastatic Colorectal Cancer
Phase 1TerminatedNovartis Pharmaceuticals132014-07-282019-01-22
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
INC280, Buparlisib - c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM
Phase 1 / Phase 2TerminatedNovartis Pharmaceuticals432014-01-092018-05-30
INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer
INC280, erlotinib hydrochloride - Recurrent Non-small Cell Lung Cancer
Phase 1CompletedUniversity of California, Davis352013-08-272021-10-13
Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
INC280 - Solid Tumors
Phase 1CompletedNovartis Pharmaceuticals1312012-02-292020-12-19
A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors
INC280 - Advanced Solid Tumor
Phase 1CompletedNovartis Pharmaceuticals442012-02-012020-12-19

Conditions studied

Carcinoma, Non-Small-Cell Lung (4)  ·  Glioblastoma (3)  ·  Colorectal Neoplasms (2)  ·  Gliosarcoma (2)  ·  Neoplasms (2)  ·  Brain Neoplasms (1)  ·  Carcinoma, Renal Cell (1)  ·  Carcinoma, Squamous Cell (1)  ·  Laryngeal Diseases (1)  ·  Liver Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Rectal Neoplasms (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

Novartis Pharmaceuticals (12)  ·  Collin Blakely (1)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)  ·  SCRI Development Innovations, LLC (1)  ·  University of California, Davis (1)

Countries

United States (12)  ·  Italy (9)  ·  Spain (9)  ·  Germany (7)  ·  France (6)  ·  Canada (5)  ·  Netherlands (5)  ·  Hong Kong (4)  ·  Singapore (4)  ·  Taiwan (4)  ·  United Kingdom (4)  ·  Australia (3)  ·  Denmark (3)  ·  South Korea (3)  ·  Austria (2)

Top investigators

Birgit Geoerger, MD (1)  ·  Collin M Blakely, MD, PhD (1)  ·  Karen Kelly (1)  ·  Kent C. Shih, M.D. (1)

Results publications

PMID 26825170, PMID 31538815, PMID 31776899, PMID 31778267, PMID 32240796, PMID 32410080, PMID 33892407, PMID 34046915, PMID 34053700, PMID 34347542, PMID 34543871, PMID 35292802, PMID 38617599, PMID 38986421, PMID 41838385, PMID 42686334

NIH funding

2014 (2), 2016 (2), 2015 (1), 2018 (1), P30CA093373 (1)